HEMA Biologics Receives FDA License for New Recombinant Factor VIIa Product

January 10, 2017

Note: The following is edited from a press release from Read the full press release in it’s entirety here. HEMA Biologics, LLC announced that the FDA has accepted the Biologics License Application(BLA) for their first potential product for commercialization in the United States.  The acceptance of the BLA for Coagulation Factor VIIa, Recombinant (eptacog beta […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.